NCT06458712

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Phase IRecruitingDuke Street Bio Ltd

Advanced Cancers (breast, Ovarian, Mcrpc, Pancreatic Ductal Adenocarcinoma (pdac), Brain Mets) With Specific Mutations (homologous Recombination Deficiency)
Anophthalmia With Pulmonary Hypoplasia
Fanconi Anemia, Complementation Group D1
Fanconi Anemia, Complementation Group N

See how this trial matches your record

Connect MyChart to see which criteria your record clearly satisfies, which need a clinician’s review, and which appear to disqualify you. Your data is read in this browser tab and never sent to our servers.

Summary

Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.

Interventions

DRUGDSB2455

Eligibility

Inclusion criteria

Must be at least 18 years old

Locations

Connecticut

Yale Cancer Center - Yale New Haven Hospital
New Haven, Connecticut
Principal Investigator · 203-785-4069 · ingrid.palma@yale.edu

France

Institut Bergonie
Bordeaux, France
Principal Investigator · +33 5 56 33 33 33 · d.teyssonneau@bordeaux.unicancer.fr
Institut Godinot
Reims, France
Principal Investigator · +33326504111 · camille.mazza@reims.unicancer.fr

Hungary

Orszagos Onkologiai Intezet
Budapest, Hungary
Principal Investigator · +3612248600/3211 · galgoczy.tunde@oncol.hu

New York

Tisch Cancer Institute Icahn School of Medicine at Mount Sinai
New York, New York
Principal Investigator · 212-824-7945 · Jordan.Cuevas@mssm.edu